Patrick Fabbio
Director of Finance/CFO presso PROTARA THERAPEUTICS, INC.
Patrimonio netto: 176 561 $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jesse Shefferman | M | 52 | 7 anni | |
Luke Beshar | M | 65 | 15 anni | |
Roger Garceau | M | 70 | 13 anni | |
Lan Huang | M | 53 | 11 anni | |
David Mims | M | 60 | 5 anni | |
Jacqueline Zummo | M | 43 | 7 anni | |
Jiang Wen Majeti | M | 56 | 2 anni | |
Hannah Fry | F | 34 | 4 anni | |
Mary J. Grendell | F | - | - | |
Brendan Delaney | M | 49 | 3 anni | |
Jane Huang | M | 51 | 3 anni | |
Matthew Kirkby | M | 55 | 8 anni | |
Gregory Sargen | M | 59 | 5 anni | |
Justine O'Malley | M | - | 4 anni | |
Cynthia Smith | F | 55 | 3 anni | |
Michael Solomon | M | 54 | 6 anni | |
Richard Levy | M | 66 | 5 anni | |
Barry Flannelly | M | 66 | 4 anni | |
Si Hai Xu | M | 52 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Mark Robert Baker | M | 69 | 14 anni | |
Angelo William Lovallo | M | 59 | 7 anni | |
Francois Nader | M | 67 | 7 anni | |
Peter J. Crowley | M | 65 | 10 anni | |
Nicole S. Williams | F | 79 | 12 anni | |
Pedro Granadillo | M | 77 | 5 anni | |
Edwin A. Cohen | M | - |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 13 anni |
Brendan P. Rae | M | - | 1 anni | |
Richard Brand | M | 67 | 2 anni | |
Jeff D. Edelson | M | - |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 3 anni |
Edward H. Stratemeier | M | 75 | 5 anni | |
Quan Qi Song | M | 59 | 5 anni | |
Christine Cvijic | F | 46 | 1 anni | |
Christine Mikail, | - | - | 1 anni | |
Ameet Mallik | M | 51 | 1 anni | |
Jeffrey D. Summer | M | 64 | 3 anni | |
Nanxing He | M | - | 2 anni | |
Mulong Liu | M | - | 2 anni | |
Jeffrey Vacirca | M | 55 | 2 anni | |
James Tonra | M | - | - | |
Daniel Zabrowski | M | 64 | 2 anni | |
Ann MacDougall | F | 70 | 1 anni | |
Shannon Klinger | M | 53 | 1 anni | |
David Scheinberg | M | 68 | 25 anni | |
Ramon Mohanlal | M | 65 | 8 anni | |
Bradley Campbell | M | 48 | 4 anni | |
Colin Broom | M | 68 | 6 anni | |
Michael Bonney | M | 65 | 10 anni | |
Michael Kishbauch | M | 75 | 6 anni | |
Donald E. Kuhla | M | 81 | 21 anni | |
Ravindra Majeti | M | 51 | 1 anni | |
Eric Ende | M | 55 | 1 anni | |
Patrik Florencio | M | - | 1 anni | |
Glenn R. Melrose | M | 68 | 2 anni | |
Yanbin Xie | M | 65 | 7 anni | |
Christine Zhao | F | 51 | 7 anni | |
Alyssa Wyant | F | 49 | 3 anni | |
Jill Quigley | F | 49 | 3 anni | |
Marcio Souza | M | 45 | 2 anni | |
Elizabeth Czerepak | F | 58 | 2 anni | |
Mary Margaret Huizinga | M | 47 | 1 anni | |
Asha Das | M | 59 | - | |
Dong Heng Liu | M | 42 | 2 anni | |
Aseem Anand | M | - | - | |
Syed Mahmood | M | - | - | |
Vishal Kapoor | M | 48 | 1 anni | |
Eric Pauwels | M | 63 | 4 anni | |
Paul Friel | M | - | 2 anni | |
Melissa Lozner | F | - | 1 anni | |
Jathin Bandari | M | 37 | 4 anni | |
Mark Santos | M | 63 | 1 anni | |
Leah Neufeld | F | - | 1 anni | |
Dhiren D'silva | M | - | 2 anni | |
Ellen Rosenberg | F | 61 | - | |
Richard Daly | M | 62 | 6 anni | |
Kathleen Boziwick | F | - |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 4 anni |
Robert Mark Weisskoff | M | 61 |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 5 anni |
G. Kenneth Lloyd | M | 80 | 9 anni | |
Gordon Leroy Schooley | M | 77 | 9 anni | |
Nitya G. Ray | M | 71 | 17 anni | |
Pierre Legault | M | 63 | 1 anni | |
Peter Young | M | 74 |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 4 anni |
Timothy I. Mitchell | M | - |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 5 anni |
Paul Firuta | M | 58 | 1 anni | |
Scott Wilhoit | M | 61 | 2 anni | |
Susan M. Mesco | F | - | 7 anni | |
Bruce Peacock | M | 72 |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | - |
Ralf H. Rosskamp | M | 71 | 2 anni | |
Kenneth Bahrt | M | 71 | 1 anni | |
G. Steven Burrill | M | 79 |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | - |
Brandi Robinson | F | - | 1 anni | |
Raouf Ghaderi | M | - |
Ikano Therapeutics, Inc.
Ikano Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing. | 4 anni |
Gérard Ber | M | 66 | 1 anni | |
Heinz Christoph Mäusli | M | 61 | 1 anni | |
Robin D. Friedman | F | - | 1 anni | |
Ashok Marin | M | 56 | 1 anni | |
Robert L. Crotty | M | 50 | 3 anni | |
Susan Graf | F | 52 | 2 anni | |
Gregg Russo | M | - | 2 anni | |
Sheldon Hirt | M | 60 | 1 anni | |
Kristy Rosse | F | - | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Patrick Fabbio
- Contatti personali